Franklin Biotechnology DiscvI(acc)EUR-H1 |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 27.3 | -17.5 | -14.4 | 15.5 | 3.8 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 16/05/2024 | EUR 24.80 | |
Day Change | -0.20% | |
Morningstar Category™ | Other Equity | |
ISIN | LU0889565759 | |
Fund Size (Mil) 30/04/2024 | USD 1625.86 | |
Share Class Size (Mil) 16/05/2024 | EUR 7.77 | |
Max Initial Charge | - | |
Ongoing Charge 04/03/2024 | 0.96% |
Investment Objective: Franklin Biotechnology DiscvI(acc)EUR-H1 |
The Fund’s investment objective is capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Wendy Lam 01/09/2018 | ||
Click here to see others | ||
Inception Date 26/02/2013 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Franklin Biotechnology DiscvI(acc)EUR-H1 | 30/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 7.08 |
Regeneron Pharmaceuticals Inc | Healthcare | 6.34 |
Vertex Pharmaceuticals Inc | Healthcare | 5.39 |
Ascendis Pharma A/S ADR | Healthcare | 4.07 |
AstraZeneca PLC ADR | Healthcare | 3.69 |
Increase Decrease New since last portfolio | ||
Franklin Biotechnology DiscvI(acc)EUR-H1 |